Genes & CellsGenes & CellsГены и КлеткиGenes and Cells2313-18292500-2562Human Stem Cells Institute69626110.17816/gc696261Original Study ArticlesОригинальные исследованияUnknownIdentification of Major Histocompatibility Complex Class I Ligands in Ovarian AdenocarcinomasИдентификация лигандов главного комплекса гистосовместимости I класса опухолей аденокарциномы яичникаhttps://orcid.org/0009-0005-6924-3435IgnatevaAgataИгнатьеваАгата Владимировнаagatyxa@gmail.comhttps://orcid.org/0000-0001-9026-6934KuznetsovAlexanderКузнецовАлександр Андреевичalexandr.kouznetsov.98@gmail.comhttps://orcid.org/0009-0004-9108-69695259-2320KudriavskiiViacheslavКудрявскийВячеслав Валерьевичwkudriavskii@gmail.comhttps://orcid.org/0000-0002-2957-39401285-4359AleshikovaOlgaАлешиковаОльга Ивановнаolga.aleshikova@gmail.comhttps://orcid.org/0000-0002-4654-95124712-0719BabaevaNataliyaБабаеваНаталия Александровнаnatbabaeva@yandex.ruhttps://orcid.org/0000-0001-6396-49484870-1626AshrafyanLevАшрафянЛев АндреевичLevaa2004@yahoo.comhttps://orcid.org/0000-0001-9156-29382868-5902ShenderVictoriaШендерВиктория Олеговнаvictoria.shender@gmail.comhttps://orcid.org/0000-0003-2323-18595871-4438ArapidiGeorgijАрапидиГеоргий Павловичarapidi@gmail.com090620262121411202512032026Copyright ©; , Eco-VectorCopyright ©; , Эко-ВекторEco-VectorЭко-Векторhttps://eco-vector.com/for_authors.php#07https://genescells.ru/2313-1829/article/view/696261

BACKGROUND. Ovarian adenocarcinoma is characterized by a high mortality rate due to late diagnosis and the development of resistance to standard chemotherapy. Despite the introduction of targeted therapies, the risk of recurrence remains high, highlighting the need for new therapeutic approaches. In this view, immunotherapy is a promising approach, but requires the identification of specific tumor antigens.

AIM. To identify tumor antigens in ovarian adenocarcinoma that are promising for immunotherapy.

METHODS. Immunopeptidome from cell lines and postoperative material of patients with ovarian adenocarcinoma were isolated using immunoaffinity chromatography followed by liquid chromatography-mass spectrometry analysis.

RESULTS. In this study, we tested an affinity chromatography-based immunopeptidome isolation protocol, comparing various detergents (CHAPS, NP-40, SOD, and Triton X-100) for cell lysis, and observed no statistically significant differences in the number of identified peptides. Using NP-40, 5 peptides belonging to the proteins of cancer/testis antigens (CTA) were identified in the immunopeptidomes of postoperative material from patients with ovarian adenocarcinoma, 3 of which, according to the human protein atlas, are indeed not expressed in normal ovarian tissues.

CONCLUSION. Each of the four tested detergents provides identification of unique sets of peptides. Immunopeptidome analysis allows the identification of peptides of CTA proteins, but a larger sample of postoperative material from patients with ovarian adenocarcinoma and experimental testing of the immunogenicity of the identified peptides are needed for further research.

Обоснование. Аденокарцинома яичника характеризуется высокой летальностью, что обусловлено поздней диагностикой и развитием резистентности к стандартной химиотерапии. Несмотря на внедрение таргетных препаратов, риск рецидива остается высоким, что обусловливает необходимость в новых терапевтических подходах. Перспективным направлением является иммунотерапия, для которой необходимо идентифицировать специфические опухолевые антигены.

Цель. Идентифицировать опухолевые антигены аденокарциномы яичника, перспективные для иммунотерапии.

Методы. Иммунопептидом клеточных линий и постоперационного материала пациентов с аденокарциномой яичника выделяли при помощи иммуно-аффинной хроматографии с последующим хромато-масс-спектрометрическим анализом.

Результаты. В этой работе мы тестировали протокол иммунно-аффинного выделения иммунопептидома, сравнивая различные детергенты (CHAPS, NP-40, SOD и Triton X-100) для лизиса клеток, и не наблюдали статистически значимых отличий в количестве идентифицируемых пептидов. Используя NP-40, в иммунопептидомах постоперационного материала пациентов с аденокарциномой яичника идентифицировали 5 пептидов, принадлежащих белкам опухоль-тестикулярных антигенов (CTA, Cancer-Testis Antigen), 3 из которых, согласно ​​атласу белков человека (The human protein atlas), действительно не экспрессируются в нормальных тканях яичников.

Заключение.

Использование каждого из четырех простестированных детергентов приводит к идентификации уникальных наборов пептидов. Анализ иммунопептидома позволяет идентифицировать пептиды, относящиеся к белкам CTA, однако необходимо увеличение выборки постоперационного материала пациентов с аденокарциномой яичника и экспериментальная проверка иммуногенности идентифицированных пептидов.

Immunopeptidome, Ovarian adenocarcinoma, affinity chromatography, HLA I ligands, mass spectrometryИммунопептидом, аденокарцинома яичника, иммуноаффинная хроматография, лиганды HLA I, масс-спектрометрияGupta KK, Gupta VK, Naumann RW. Ovarian cancer: screening and future directions. Int J Gynecol Cancer 2019;29:195–200. https://doi.org/10.1136/ijgc-2018-000016.Sjoquist KM, Lord SJ, Friedlander ML, John Simes R, Marschner IC, Lee CK. Progression-free survival as a surrogate endpoint for overall survival in modern ovarian cancer trials: a meta-analysis. Ther Adv Med Oncol 2018;10:1758835918788500. https://doi.org/10.1177/1758835918788500.Lu Y, Wang A, Shi P, Zhang H, Li Z. Quantum chemical study on the antioxidation mechanism of piceatannol and isorhapontigenin toward hydroxyl and hydroperoxyl radicals. PLoS One 2015;10:e0133259. https://doi.org/10.1371/journal.pone.0133259.Caruso G, Weroha SJ, Cliby W. Ovarian cancer: A review: A review. JAMA 2025;334:1278–91. https://doi.org/10.1001/jama.2025.9495.Wick W, Dietrich P-Y, Kuttruff S, Hilf N, Frenzel K, Admon A, van der Burg SH, von Deimling A, Gouttefangeas C, Kroep JR, Martinez-Ricarte F, Okada H, Ottensmeier CHH, Ponsati B, Poulsen HS, Stevanovic S, Tabatabai G, Rammensee H-G, Sahin U, Singh H, GAPVAC Consortium. GAPVAC-101: First-in-human trial of a highly personalized peptide vaccination approach for patients with newly diagnosed glioblastoma. J Clin Oncol 2018;36:2000–2000. https://doi.org/10.1200/jco.2018.36.15_suppl.2000.Kandalaft LE, Powell DJ Jr, Singh N, Coukos G. Immunotherapy for ovarian cancer: what’s next? J Clin Oncol 2011;29:925–33. https://doi.org/10.1200/JCO.2009.27.2369.Raja R, Mangalaparthi KK, Madugundu AK, Jessen E, Pathangey L, Magtibay P, Butler K, Christie E, Pandey A, Curtis M. Immunogenic cryptic peptides dominate the antigenic landscape of ovarian cancer. Sci Adv 2025;11:eads7405. https://doi.org/10.1126/sciadv.ads7405.Chiaro J, Peltonen K, Õunap K, Bailey A, Feola S, Wojciechowski S, Es-Haghi M, Azkargorta M, Elortza F, Russo S, Sallinen H, Anttila M, Gurvich O, Cerullo V, Kekarainen T. Proteogenomic approach to immunopeptidomics of ovarian tumors identifies shared peptide vaccine candidates. NPJ Vaccines 2025;10:195. https://doi.org/10.1038/s41541-025-01234-6.Schuster H, Peper JK, Bösmüller H-C, Röhle K, Backert L, Bilich T, Ney B, Löffler MW, Kowalewski DJ, Trautwein N, Rabsteyn A, Engler T, Braun S, Haen SP, Walz JS, Schmid-Horch B, Brucker SY, Wallwiener D, Kohlbacher O, Fend F, Rammensee H-G, Stevanović S, Staebler A, Wagner P. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A 2017;114:E9942–51. https://doi.org/10.1073/pnas.1707658114.Purcell AW, Ramarathinam SH, Ternette N. Mass spectrometry-based identification of MHC-bound peptides for immunopeptidomics. Nat Protoc 2019;14:1687–707. https://doi.org/10.1038/s41596-019-0133-y.Sirois I, Isabelle M, Duquette JD, Saab F, Caron E. Immunopeptidomics: Isolation of mouse and human MHC class I- and II-associated peptides for mass spectrometry analysis. J Vis Exp 2021. https://doi.org/10.3791/63052-v.Chong C, Marino F, Pak H, Racle J, Daniel RT, Müller M, Gfeller D, Coukos G, Bassani-Sternberg M. High-throughput and sensitive immunopeptidomics platform reveals profound interferonγ-mediated remodeling of the human leukocyte antigen (HLA) ligandome. Mol Cell Proteomics 2018;17:533–48. https://doi.org/10.1074/mcp.TIR117.000383.Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res 2020;48:W449–54. https://doi.org/10.1093/nar/gkaa379.Kuznetsov A, Voronina A, Govorun V, Arapidi G. Critical review of existing MHC I immunopeptidome isolation methods. Molecules 2020;25:5409. https://doi.org/10.3390/molecules25225409.Vizcaíno JA, Kubiniok P, Kovalchik KA, Ma Q, Duquette JD, Mongrain I, Deutsch EW, Peters B, Sette A, Sirois I, Caron E. The Human Immunopeptidome Project: A roadmap to predict and treat immune diseases. Mol Cell Proteomics 2020;19:31–49. https://doi.org/10.1074/mcp.R119.001743.Nicastri A, Liao H, Muller J, Purcell AW, Ternette N. The choice of HLA-associated peptide enrichment and purification strategy affects peptide yields and creates a bias in detected sequence repertoire. Proteomics 2020;20:e1900401. https://doi.org/10.1002/pmic.201900401.Klein E, Ben-Bassat H, Neumann H, Ralph P, Zeuthen J, Polliack A, Vánky F. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 1976;18:421–31. https://doi.org/10.1002/ijc.2910180405.Arshad S, Cameron B, Joglekar AV. Immunopeptidomics for autoimmunity: unlocking the chamber of immune secrets. NPJ Syst Biol Appl 2025;11:10. https://doi.org/10.1038/s41540-024-00482-x.Willems P, Thery F, Van Moortel L, De Meyer M, Staes A, Gul A, Kovalchuke L, Declercq A, Devreese R, Bouwmeester R, Gabriels R, Martens L, Impens F. Maximizing immunopeptidomics-based bacterial Epitope discovery by multiple search engines and rescoring. J Proteome Res 2025;24:2141–51. https://doi.org/10.1021/acs.jproteome.4c00864.Leddy OK, White FM, Bryson BD. Leveraging immunopeptidomics to study and combat infectious disease. mSystems 2021;6:e0031021. https://doi.org/10.1128/mSystems.00310-21.Tretter C, de Andrade Krätzig N, Pecoraro M, Lange S, Seifert P, von Frankenberg C, Untch J, Zuleger G, Wilhelm M, Zolg DP, Dreyer FS, Bräunlein E, Engleitner T, Uhrig S, Boxberg M, Steiger K, Slotta-Huspenina J, Ochsenreither S, von Bubnoff N, Bauer S, Boerries M, Jost PJ, Schenck K, Dresing I, Bassermann F, Friess H, Reim D, Grützmann K, Pfütze K, Klink B, Schröck E, Haller B, Kuster B, Mann M, Weichert W, Fröhling S, Rad R, Hiltensperger M, Krackhardt AM. Proteogenomic analysis reveals RNA as a source for tumor-agnostic neoantigen identification. Nat Commun 2023;14:4632. https://doi.org/10.1038/s41467-023-39570-7.Cai Y, Gong M, Zeng M, Leng F, Lv D, Guo J, Wang H, Li Y, Lin Q, Jing J, Zhang Y, Xu J, Li Y. Immunopeptidomics-guided discovery and characterization of neoantigens for personalized cancer immunotherapy. Sci Adv 2025;11:eadv6445. https://doi.org/10.1126/sciadv.adv6445.Gurung HR, Heidersbach AJ, Darwish M, Chan PPF, Li J, Beresini M, Zill OA, Wallace A, Tong A-J, Hascall D, Torres E, Chang A, Lou K ’hei-Wai', Abdolazimi Y, Hammer C, Xavier-Magalhães A, Marcu A, Vaidya S, Le DD, Akhmetzyanova I, Oh SA, Moore AJ, Uche UN, Laur MB, Notturno RJ, Ebert PJR, Blanchette C, Haley B, Rose CM. Systematic discovery of neoepitope-HLA pairs for neoantigens shared among patients and tumor types. Nat Biotechnol 2024;42:1107–17. https://doi.org/10.1038/s41587-023-01945-y.Spizzo G, Fong D, Wurm M, Ensinger C, Obrist P, Hofer C, Mazzoleni G, Gastl G, Went P. EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 2011;64:415–20. https://doi.org/10.1136/jcp.2011.090274.Charkhchi P, Cybulski C, Gronwald J, Wong FO, Narod SA, Akbari MR. CA125 and ovarian cancer: A comprehensive review. Cancers (Basel) 2020;12:3730. https://doi.org/10.3390/cancers12123730.Bassani-Sternberg M, Bräunlein E, Klar R, Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J, Slotta-Huspenina J, Specht K, Martignoni ME, Werner A, Hein R, H Busch D, Peschel C, Rad R, Cox J, Mann M, Krackhardt AM. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat Commun 2016;7:13404. https://doi.org/10.1038/ncomms13404.Shraibman B, Barnea E, Kadosh DM, Haimovich Y, Slobodin G, Rosner I, López-Larrea C, Hilf N, Kuttruff S, Song C, Britten C, Castle J, Kreiter S, Frenzel K, Tatagiba M, Tabatabai G, Dietrich P-Y, Dutoit V, Wick W, Platten M, Winkler F, von Deimling A, Kroep J, Sahuquillo J, Martinez-Ricarte F, Rodon J, Lassen U, Ottensmeier C, van der Burg SH, Thor Straten P, Poulsen HS, Ponsati B, Okada H, Rammensee H-G, Sahin U, Singh H, Admon A. Identification of tumor antigens among the HLA peptidomes of glioblastoma tumors and plasma. Mol Cell Proteomics 2019;18:1255–68. https://doi.org/10.1074/mcp.RA119.001524.Whitehurst AW. Cause and consequence of cancer/testis antigen activation in cancer. Annu Rev Pharmacol Toxicol 2014;54:251–72. https://doi.org/10.1146/annurev-pharmtox-011112-140326.Gomez-Zepeda D, Arnold-Schild D, Beyrle J, Declercq A, Gabriels R, Kumm E, Preikschat A, Łącki MK, Hirschler A, Rijal JB, Carapito C, Martens L, Distler U, Schild H, Tenzer S. Thunder-DDA-PASEF enables high-coverage immunopeptidomics and is boosted by MS2Rescore with MS2PIP timsTOF fragmentation prediction model. Nat Commun 2024;15:2288. https://doi.org/10.1038/s41467-024-46380-y.Beyrle J, Distler U, Gomez-Zepeda D, Tenzer S. MAETi: Mild acid elution in a tip enables immunopeptidome profiling from 25,000 cells. Immunology 2024.Ternette N, Block PD, Sánchez-Bernabéu Á, Borthwick N, Pappalardo E, Abdul-Jawad S, Ondondo B, Charles PD, Dorrell L, Kessler BM, Hanke T. Early kinetics of the HLA class I-associated peptidome of MVA.HIVconsv-infected cells. J Virol 2015;89:5760–71. https://doi.org/10.1128/JVI.03627-14.Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M. NetMHCpan-4.0: Improved peptide-MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol 2017;199:3360–8. https://doi.org/10.4049/jimmunol.1700893.Capietto A-H, Hoshyar R, Delamarre L. Sources of cancer neoantigens beyond single-nucleotide variants. Int J Mol Sci 2022;23:10131. https://doi.org/10.3390/ijms231710131.Darrigrand R, Pierson A, Rouillon M, Renko D, Boulpicante M, Bouyssié D, Mouton-Barbosa E, Marcoux J, Garcia C, Ghosh M, Alami M, Apcher S. Isoginkgetin derivative IP2 enhances the adaptive immune response against tumor antigens. Commun Biol 2021;4:269. https://doi.org/10.1038/s42003-021-01801-2.Anufrieva KS, Shender VО, Arapidi GP, Pavlyukov MS, Shakhparonov MI, Shnaider PV, Butenko IO, Lagarkova MA, Govorun VM. Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells. Genome Med 2018;10:49. https://doi.org/10.1186/s13073-018-0557-y.Melacarne A, Ferrari V, Tiraboschi L, Mishto M, Liepe J, Aralla M, Marconato L, Lizier M, Pozzi C, Zeira O, Penna G, Rescigno M. Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. Cell Reports 2021;36:109312. https://doi.org/10.1016/j.celrep.2021.109312.Kwok DW, Stevers NO, Etxeberria I, Nejo T, Colton Cove M, Chen LH, Jung J, Okada K, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Liu J, Wu SH, Ramos E, Yamamichi A, Watchmaker PB, Ogino H, Saijo A, Du A, Grishanina NR, Woo J, Diaz A, Hervey-Jumper SL, Chang SM, Phillips JJ, Wiita AP, Klebanoff CA, Costello JF, Okada H. Tumour-wide RNA splicing aberrations generate actionable public neoantigens. Nature 2025;639:463–73. https://doi.org/10.1038/s41586-024-08552-0.Uchihara Y, Permata TBM, Sato H, Kawabata-Iwakawa R, Katada S, Gu W, Kakoti S, Yamauchi M, Kato R, Gondhowiardjo S, Hosen N, Yasuhara T, Shibata A. DNA damage promotes HLA class I presentation by stimulating a pioneer round of translation-associated antigen production. Mol Cell 2022;82:2557–70.e7. https://doi.org/10.1016/j.molcel.2022.04.030.